Biotech Values

[DewDiligence]

MNTA exercises AnaptysBio option to further IVIG program:

http://finance.yahoo.com/news/momenta-pharmaceuticals-exercises-option-acquire-123000665.html

Momenta Pharmaceuticals, Inc…today announced that it has exercised its option to acquire novel antibodies generated by AnaptysBio, Inc., a privately-held therapeutic antibody company, as part of the previously announced agreement between the two companies.

"The antibodies generated by AnaptysBio allow us to further progress our development of a novel recombinant antibody for certain autoimmune disorders," said Ganesh Kaundinya, Ph.D., Chief Scientific Officer of Momenta Pharmaceuticals, Inc. "The target for the antibodies was selected based on Momenta's research of the complex biology underlying the anti-inflammatory effects of IVIg. As a result of this research, we engaged AnaptysBio to engineer a novel recombinant antibody that targets a specific biological pathway we believe is important for autoimmune diseases.

We look forward to sharing more details of this program and our other lead programs in the autoimmune disease area at our R&D day in October.

MNTA’s R&D Day is on 10/10/14.